The Effects of Oregano Oil on Fungal Infections Associated with Metabolic Syndrome
Résumé
This study aims to compare the evolution of mycosis associated with metabolic syndrome under allopathic treatment compared to phytotherapy using oregano essential oil. The study was conducted over a period of 6 months, on a total of 72 patients diagnosed with fungal infections associated with metabolic syndrome. The patients were divided into 3 groups, depending on the administered treatment: group 1: 24 patients who received allopathic treatment; group 2: 24 patients who received oregano oil treatment; group 3: control, which did not undergo any antifungal treatment. All three groups were subjected to specific diet therapy for mycosis. The patients were initially evaluated at 10 days after the begining of the treatment (to track mycotic disease evolution in the acute phase), at 60 days (to evaluate the recurrence of mycoses) and at 180 days to track recurrent disease. Most infections were acute (77.78%), the chronic ones representing only 5.56% of cases. There were also 12 cases with recurrent infections (16.67%), out of which 6 cases (8.33%) had previously shown resistance to Nystatin. In the 72 cases there was a sensitivity of 100.00% for oregano oil and Ketaconazolum, insignificantly higher than for Myconazolum (97.22%, p=0.157), but significantly higher than for Clotrimazolum and Nystatinum (94.44%, p=0.0437), Variconazole and Fluconazole (88.89%, p=0.0038) and Itraconazole (86.11%, p=0.0011). The results of this study showed an increased efficiency of oregano oil on the symptomatic and paraclinical improvement of mycotic infections in the study, both on short term and on long term, which was completed with high tolerability.